Core Viewpoint - The company, 心玮医疗-B (06609), anticipates significant revenue growth for the fiscal year ending December 31, 2025, projecting earnings between approximately RMB 400 million and RMB 410 million, representing an increase of at least 43.9% compared to RMB 278 million for the fiscal year ending December 31, 2024 [1] Revenue Growth Drivers - The revenue growth is driven by the launch of new products and technologies for ischemic stroke and an increase in market share for ischemic stroke products [1] - The commercialization of intracranial stents and increased sales of other hemorrhagic stroke products contribute to the revenue growth [1] - Continuous growth in sales of interventional access products also supports the revenue increase [1] - Effective cost control measures in sales costs and administrative expenses have reduced the company's expense ratio [1] Profitability Expectations - The company expects to achieve a pre-tax profit of approximately RMB 80 million during the reporting period, a significant improvement compared to a pre-tax net loss of RMB 12 million for the fiscal year ending December 31, 2024 [1]
心玮医疗-B发盈喜 预期2025年收益约4亿元至4.1亿元 同比增加至少43.9%